Form 4: Gilead Sciences Chief Commercial Officer Sells 5,000 Shares

Johanna Mercier, Chief Commercial Officer of Gilead Sciences, sold 5,000 shares of common stock at a price of $91.28 per share on November 6, 2024, according to a Form 4 filing with the SEC.

Summary

• On November 6, 2024, Johanna Mercier, the Chief Commercial Officer of Gilead Sciences, sold 5,000 shares of the company's common stock.
• The sale was executed at a price of $91.28 per share.
• Following the transaction, Mercier directly owns 73,127 shares of Gilead Sciences common stock.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on April 30, 2024.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting a stock sale by an executive. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.

Industry Context

Executive stock sales are a common occurrence and are often related to personal financial planning. The use of a 10b5-1 trading plan suggests the sale was pre-planned and not based on insider information.

Stakeholder Impact

• The stock sale by a high-ranking officer could be perceived negatively by some shareholders, although the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates